APPLICATION
ANDA078452
TYPE
ANDA
ORIGINAL APPROVAL
2009-09-04
LATEST ACTION
2023-08-09
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
RISPERIDONEPrescription
RISPERIDONE 1MG/ML · SOLUTION · ORAL
Approval history
2023-08-09Labeling · Supplement 12 · standardAP
2023-08-08Labeling · Supplement 16 · standardAP
2020-07-13Labeling · Supplement 8 · standardAP
2020-07-13Labeling · Supplement 6 · standardAP
2020-07-13Labeling · Supplement 11 · standardAP
2020-07-13Labeling · Supplement 9 · standardAP
2020-07-13Labeling · Supplement 7 · standardAP
2015-04-23Manufacturing (CMC) · Supplement 5 · unknownAP
2012-10-22Labeling · Supplement 4 · standardAP
2012-01-30Labeling · Supplement 3AP
2011-11-10Labeling · Supplement 2AP
2011-04-19Labeling · Supplement 1AP
2009-09-04OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.